News | Heart Valve Technology | April 17, 2024

CPR-Therapeutics, Inc. Names Mike Black as Chief Strategy Officer

Mike Black

Mike Black


April 17, 2024 —CPR Therapeutics, Inc. (CPR-T), an early-stage medtech startup funded by the N.I.H and N.S.F to develop the next generation technology for cardiopulmonary resuscitation, announced today that Mike Black will be advising the Company as its first Chief Strategy Officer.

CPR Therapeutics, Inc. is developing multimodal cardiopulmonary resuscitation (CPR), a more effective form of automated mechanical CPR. Sudden cardiac arrest is one of the leading causes of sudden death worldwide and there are currently no devices more effective than manual chest compressions. Intact survival after cardiac arrest is below 10% in most communities.

Dave Gaddy, CPR Therapeutic’s CEO said “We could not be more excited to have Mike’s expertise. His background in leading the development of innovative resuscitation and EMS medical devices is uniquely strong. He was CEO of Advanced Circulatory Systems Inc. (ACSI), one of the few start-ups to innovate significantly in CPR. He went on to be Vice President of Global Customer Experience at ZOLL Medical, a leading strategic company in EMS that acquired ACSI in 2015.”

Asked to share his perspective on CPR-T, Mike responded “I’m looking forward to advising the CPR Therapeutics team on the development of this important suite of medical technologies. I have a long-term commitment to improving the outcome of patients suffering cardiac arrest. CPR-T’s approach is a major opportunity to advance care and have a meaningful impact on one of the leading killers worldwide.”

Dr. Paradis, CPR-T’s Founder and Chief Medical Officer added: “Mike is a great fit for helping our start-up company take on one of medicine’s most intractable problems – improving the efficacy of CPR. I genuinely believe our chances for success go up significantly having Mike in this important role.”

For more information: www.cprtherapeutics.com


Related Content

Feature | Heart Failure | Kyle Hardner

Editor's Note: This is Part Three of a three-part series highlighting several of the presentations from the American ...

Home May 13, 2026
Home
News | Heart Failure

May 10, 2026 — Results from the first randomized trial evaluating microRNA inhibition in heart failure were presented ...

Home May 11, 2026
Home
Feature | Heart Failure | Kyle Hardner

Could a link between the heart, brain and immune system help reduce the occurrence of heart attacks and lessen the ...

Home May 04, 2026
Home
News | Heart Failure

April 21, 2026 — Nuwellis, Inc. has announced a software update to its Aquadex SmartFlow ultrafiltration platform. The ...

Home April 23, 2026
Home
News | Heart Failure

March 28, 2026 — Amgen announced today that Repatha (evolocumab), when added to statins or other low-density lipoprotein ...

Home April 06, 2026
Home
News | Heart Failure

March 24, 2026 — New research shows that small improvements to sleep, diet quality and physical activity, made in ...

Home March 25, 2026
Home
News | Heart Failure

March 16, 2026 — Cytokinetics has announced four presentations related to Myqorzo (aficamten) at the American College of ...

Home March 16, 2026
Home
Feature | Heart Failure | Rohit Sood, MD, PhD

Cardiovascular disease (CVD) is a serious global health burden that encompasses a broad group of diseases that affect ...

Home February 12, 2026
Home
News | Heart Failure

Feb. 3, 2026 — Bristol Myers Squibb has launched "Change the Target. Change What’s Possible," an educational campaign ...

Home February 03, 2026
Home
News | Heart Failure

Jan. 27, 2026 — A new national study reveals a stark disconnect between Americans’ desire for preventive cardiac ...

Home January 27, 2026
Home
Subscribe Now